Literature DB >> 9315657

Leishmania major Hsp100 is required chiefly in the mammalian stage of the parasite.

A Hübel1, S Krobitsch, A Hörauf, J Clos.   

Abstract

In Leishmania major a 100-kDa heat shock protein, Hsp100, is abundant in the intracellular amastigote stage which persists in the mammalian host. A replacement of both clpB alleles which encode Hsp100 does not affect promastigote viability under standard culture conditions but impairs thermotolerance in vitro. In experimental infections of BALB/c inbred mice, the lack of Hsp100 in the gene replacement mutants results in a markedly delayed lesion development compared with that in infections with wild-type L. major. Overexpression of exogenous clpB gene copies can partly restore virulence to the gene replacement mutants. Genetic-selection experiments also reveal a strong pressure for Hsp100 expression in the mammalian stage. This requirement for Hsp100 was also observed in in vitro infection experiments with mouse peritoneal macrophages. These experiments indicated a role for Hsp100 during the development from the promastigote to the amastigote stage. Our results suggest an important role for this parasite heat shock protein during the initial stages of a mammalian infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9315657      PMCID: PMC232447          DOI: 10.1128/MCB.17.10.5987

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  39 in total

Review 1.  Heat shock proteins in host-parasite interactions.

Authors:  B S Polla
Journal:  Immunol Today       Date:  1991-03

2.  Protein disaggregation mediated by heat-shock protein Hsp104.

Authors:  D A Parsell; A S Kowal; M A Singer; S Lindquist
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

3.  Cloning and characterization of differentially expressed genes from in vitro-grown 'amastigotes' of Leishmania donovani.

Authors:  M Joshi; D M Dwyer; H L Nakhasi
Journal:  Mol Biochem Parasitol       Date:  1993-04       Impact factor: 1.759

4.  The genomic organization of the HSP83 gene locus is conserved in three Leishmania species.

Authors:  A Hübel; J Clos
Journal:  Exp Parasitol       Date:  1996-03       Impact factor: 2.011

5.  Improvements in the isolation of IgY from the yolks of eggs laid by immunized hens.

Authors:  A Polson; T Coetzer; J Kruger; E von Maltzahn; K J van der Merwe
Journal:  Immunol Invest       Date:  1985-08       Impact factor: 3.657

6.  HSP104 required for induced thermotolerance.

Authors:  Y Sanchez; S L Lindquist
Journal:  Science       Date:  1990-06-01       Impact factor: 47.728

7.  Axenic culture of Leishmania amastigotes.

Authors:  P A Bates
Journal:  Parasitol Today       Date:  1993-04

8.  Pathophysiology of experimental leishmaniasis: pattern of development of metastatic disease in the susceptible host.

Authors:  J O Hill
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

9.  Transfection and continuous expression of heterologous genes in the protozoan parasite Entamoeba histolytica.

Authors:  L Hamann; R Nickel; E Tannich
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

10.  Hsp104 is required for tolerance to many forms of stress.

Authors:  Y Sanchez; J Taulien; K A Borkovich; S Lindquist
Journal:  EMBO J       Date:  1992-06       Impact factor: 11.598

View more
  36 in total

1.  Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response.

Authors:  C Kébaïer; H Louzir; M Chenik; A Ben Salah; K Dellagi
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Analysis of the Leishmania donovani transcriptome reveals an ordered progression of transient and permanent changes in gene expression during differentiation.

Authors:  A Saxena; T Lahav; N Holland; G Aggarwal; A Anupama; Y Huang; H Volpin; P J Myler; D Zilberstein
Journal:  Mol Biochem Parasitol       Date:  2006-12-12       Impact factor: 1.759

3.  Reduced antimony accumulation in ARM58-overexpressing Leishmania infantum.

Authors:  Carola Schäfer; Paloma Tejera Nevado; Dorothea Zander; Joachim Clos
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

4.  A chemical inhibitor of heat shock protein 78 (HSP78) from Leishmania donovani represents a potential antileishmanial drug candidate.

Authors:  Sonali Das; Anindyajit Banerjee; Mohd Kamran; Sarfaraz Ahmad Ejazi; Mohammad Asad; Nahid Ali; Saikat Chakrabarti
Journal:  J Biol Chem       Date:  2020-05-29       Impact factor: 5.157

Review 5.  The genetics of Leishmania virulence.

Authors:  Eugenia Bifeld; Joachim Clos
Journal:  Med Microbiol Immunol       Date:  2015-06-06       Impact factor: 3.402

Review 6.  Protein quality control machinery in intracellular protozoan parasites: hopes and challenges for therapeutic targeting.

Authors:  Mohammad Anas; Varsha Kumari; Niharika Gupta; Anuradha Dube; Niti Kumar
Journal:  Cell Stress Chaperones       Date:  2019-06-21       Impact factor: 3.667

7.  Spontaneous recovery of pathogenicity by Leishmania major hsp100-/- alters the immune response in mice.

Authors:  Linda Reiling; Thomas Jacobs; Manfred Kroemer; Iris Gaworski; Sebastian Graefe; Joachim Clos
Journal:  Infect Immun       Date:  2006-11       Impact factor: 3.441

8.  The co-chaperone SGT of Leishmania donovani is essential for the parasite's viability.

Authors:  Gabi Ommen; Mareike Chrobak; Joachim Clos
Journal:  Cell Stress Chaperones       Date:  2009-12-02       Impact factor: 3.667

9.  Overexpression of a single Leishmania major gene enhances parasite infectivity in vivo and in vitro.

Authors:  Linda Reiling; Mareike Chrobak; Christel Schmetz; Joachim Clos
Journal:  Mol Microbiol       Date:  2010-03-25       Impact factor: 3.501

10.  Host cell invasion and virulence mediated by Candida albicans Ssa1.

Authors:  Jianing N Sun; Norma V Solis; Quynh T Phan; Jashanjot S Bajwa; Helena Kashleva; Angela Thompson; Yaoping Liu; Anna Dongari-Bagtzoglou; Mira Edgerton; Scott G Filler
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.